Trial reportJournal of the European Academy of Dermatology and Venereology : JEADV2026
Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitis.
Trial report in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
An Open-label, Single-arm, Multi-centre, Long-term Extension Trial to Evaluate the Safety and Efficacy of Tralokinumab in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Clinical Trials
Who cites it
4 citing papers in PubMed.
- Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Trial
- Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: a Real-World Monocentric Retrospective Study.Dermatology and therapy · 2026Article
- Atopic Dermatitis Beyond the Skin Barrier: Precision Medicine Approaches to Immunological Profiling and Therapeutic Innovation.International journal of molecular sciences · 2026Review
- Roles of interleukins in spasmolytic polypeptide‑expressing metaplasia (Review).International journal of oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundAtopic dermatitis (AD) is a relapsing and remitting skin disease often requiring long-term treatment. Tralokinumab, a monoclonal antibody specifically neutralizing interleukin-13, is approved for moderate-to-severe AD treatment in multiple countries.
objectivesAssess long-term efficacy of tralokinumab in adults with moderate-to-severe AD treated for up to 4 years.
methodsThis post hoc interim analysis included the subgroup of patients (n = 347) who completed 52 weeks of tralokinumab in the Phase 3 ECZTRA 1 or ECZTRA 2 (NCT03131648/NCT03160885) trials and subsequently enrolled in the open-label extension trial ECZTEND (NCT03587805; receiving tralokinumab plus optional topical corticosteroids/calcineurin inhibitors [TCS/TCI]) ≥152 weeks prior to data cut-off (30-April-2022).
resultsAt ECZTEND Week 152, 52.6% (95% CI 45.2; 59.8) of patients achieved Investigator's Global Assessment 0/1 (clear or almost clear skin) and 84.5% (95% CI 78.4; 89.1) achieved ≥75% improvement in Eczema Area and Severity Index (EASI) from parent trial baseline; additionally, 84.5% (95% CI 78.4; 89.1), 68.0% (95% CI 60.8; 74.5) and 79.0% (95% CI 72.1; 84.6) reached EASI ≤7 (no-to-mild disease), Worst Weekly Pruritus Numeric Rating Scale ≤4 (no-to-mild itch) and Dermatology Life Quality Index ≤5 (no-to-small effect on quality of life), respectively. Responses were stable over time, with 71.4% (95% CI 66.3; 76.0) of patients maintaining EASI ≤7 at ≥80% of days between Week 16 and 152 in ECZTEND. During ECZTEND, 28.5% of patients discontinued: 7.5% due to lack of efficacy and 5.8% due to adverse events (AEs). The most frequently reported AEs in ECZTEND were consistent with the known safety profile of tralokinumab, including nasopharyngitis (IR = 13.6), upper respiratory tract infection (IR = 4.4) and conjunctivitis (IR = 2.3).
conclusionsThese data suggest that tralokinumab plus optional TCS/TCI provides long-term stable disease control, equivalent to no-to-mild disease, in a subgroup of adults with moderate-to-severe AD who completed 1 year of treatment in parent trials and up to 3 years in ECZTEND.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.